News

Myobloc (rimabotulinumtoxinB) injections are approved by the U.S. Food and Drug Administration (FDA) to treat adults with chronic sialorrhea, or drooling, a condition often experienced by Parkinson’s patients. Myobloc, marketed by US WorldMeds, is the first botulinum toxin type B approved…

A new Phase 3 clinical trial, called the “BouNDless study,” will soon compare continuous administration of ND0612 to oral immediate-release carbidopa/levodopa (CD/LD) in people with Parkinson’s disease who are experiencing motor fluctuations, Mitsubishi Tanabe Pharma America (MTPA) announced. Both of the above-mentioned treatments work by increasing the level of…

A Phase 2 clinical trial of SEP-363856, an oral treatment candidate for patients with Parkinson’s psychosis, is recruiting participants throughout the U.S. The Sunovion-funded SEP361-203 study (NCT02969369) will be conducted at 24 U.S. sites and will include approximately 36 participants, 24 on SEP-363856 and 12…

The U.S Food and Drug Administration (FDA) has approved Kyowa Kirin’s Nourianz (istradefylline) tablets as an add-on therapy to treat off periods in Parkinson’s disease patients on a carbidopa/levodopa regimen. Off periods — when the effects of a medication wear off before a new dose can be…

With the overarching goal of helping scientists develop and test targeted therapies in Parkinson’s (PD), The Michael J. Fox Foundation (MJFF) is awarding $5 million in grants to three teams conducting genetic studies in African, East Asian and Indian populations. The funding seeks to broaden these studies in…

Patients with Parkinson’s are at a greater risk of developing impulse control disorders (ICDs) if they are depressed, according to results from an international study. The findings also revealed that treatment with dopamine agonists increases this susceptibility, and caution is advised when prescribing such therapies to depressed Parkinson’s…

Rescuing the activity of neurons in the subthalamic nucleus — part of a brain region that controls movement — lessens motor dysfunction in a mouse model of Parkinson’s disease (PD), according to a recent study. The “study argues that the loss of this intrinsic activity promotes abnormal synchronization and…

The largest dataset ever compiled on Parkinson’s disease research — equivalent to 47.5 billion single-spaced typed pages — is now available to scientists, and can be used to investigate genetic changes over time in people with the neurodegenerative disorder. Funded by the Michael J. Fox Foundation, the “Parkinson’s…

Leading the first national effort to address long-standing gender disparities in Parkinson’s (PD) research and care, the Parkinson’s Foundation has developed patient-centered recommendations to promote the needs women in the U.S. living with the disease. Drawn from the foundation’s two-year Women and PD…

A mathematical model created to more effectively prevent protein clumping, widely thought to underlie diseases like Parkinson’s, found that different potential treatments work best at different disease stages. As such, this model may help in designing and timing the use of therapies against protein aggregates, and in testing them in…